Literature DB >> 4062959

Mechanism of DNA strand breaks by mitonafide, an imide derivative of 3-nitro-1,8-naphthalic acid.

B K Sinha, J Strong, N W Gibson, B Kalyanaraman.   

Abstract

The metabolism and the mechanism of action of 5-nitro-2-(2-dimethylaminoethyl)-benzo(de) isoquinoline-1,3-dione (mitonafide), a nitro-containing antitumor drug, have been studied. Incubation of mitonafide under anaerobic conditions with rat liver microsomes and NADPH formed the fully reduced amine metabolite, 5-aminomitonafide. The formation of the amine metabolite was not inhibited by SKF-525A, metyrapone or piperonyl butoxide, indicating that the cytochrome P-450 was not involved in this reduction. Incubation of mitonafide with rat liver microsomes and NADPH under aerobic conditions stimulated oxygen consumption; piperonyl butoxide, SKF-525A, superoxide dismutase and catalase had no effect on this stimulation. Both mitonafide and 5-aminomitonafide were found to bind to DNA in a similar manner. However, in inducing single-stand breaks in the DNA of L1210 cells mitonafide was 10-fold more potent than 5-aminomitonafide. These results suggest that metabolic activation of mitonafide to species other than that of the amine metabolite may play a significant role in the induction of DNA damage and the biological activity of the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4062959     DOI: 10.1016/0006-2952(85)90433-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity.

Authors:  E Díaz-Rubio; M Martín; J M López-Vega; A Casado; A Benavides
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

2.  Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer.

Authors:  R Rosell; J Carles; A Abad; N Ribelles; A Barnadas; A Benavides; M Martin
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

3.  Phase II study of amonafide in advanced pancreatic adenocarcinoma.

Authors:  K Linke; R Pazdur; J L Abbruzzese; J A Ajani; R Winn; J E Bradof; K Daugherty; B Levin
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

4.  Phase I study of mitonafide in solid tumors.

Authors:  M Llombart; A Poveda; E Forner; C Fernández-Martos; C Gaspar; M Muñoz; T Olmos; A Ruiz; V Soriano; A Benavides
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

5.  Unique Photophysical Properties of 1,8-Naphthalimide Derivatives: Generation of Semi-stable Radical Anion Species by Photo-Induced Electron Transfer from a Carboxy Group.

Authors:  Hironori Izawa; Fumika Yasufuku; Toshiki Nokami; Shinsuke Ifuku; Hiroyuki Saimoto; Toru Matsui; Kenji Morihashi; Masato Sumita
Journal:  ACS Omega       Date:  2021-05-12

6.  Naphthalimides Selectively Inhibit the Activity of Bacterial, Replicative DNA Ligases and Display Bactericidal Effects against Tubercle Bacilli.

Authors:  Malgorzata Korycka-Machala; Marcin Nowosielski; Aneta Kuron; Sebastian Rykowski; Agnieszka Olejniczak; Marcin Hoffmann; Jaroslaw Dziadek
Journal:  Molecules       Date:  2017-01-17       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.